{ }
001122334455554433221100
001122334455554433221100

GSK invests 300 million in bispecific antibody for potential lupus treatment

GSK is set to pay $300 million to license a bispecific antibody from Chimagen Biosciences, aimed at treating autoimmune diseases like lupus. Currently in Phase 1 testing for cancer, the drug targets B cells by engaging T cells, potentially offering a novel therapeutic option for B cell-driven conditions. GSK plans to initiate its own Phase 1 trial next year, pending regulatory approval.

GSK RSV vaccine shows effectiveness over three seasons but wanes over time

GSK's RSV vaccine, Arexvy, demonstrated 63% overall efficacy and 67% against severe disease over three seasons, though effectiveness declined to 48% in the third season. The CDC currently does not recommend a second dose, but GSK anticipates that revaccination may be necessary to maintain protection. The findings will be presented at the CHEST 2024 Annual Meeting.
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.